TORII PHARMACEUTICAL CO., LTD. Under the Agreement, once the New Indication has been approved by PMDA, Torii and ASKA will jointly engage in the marketing of Riona's the New Indication. Torii will mainly focus on medical institutions with chronic kidney disease-related departments, such as nephrology and dialysis, while ASKA will mainly focus on medical institutions with obstetrics and gynecology.
As a specialty pharma company that focuses on the obstetrics and gynecology area, ASKA is striving to expand its portfolio of relevant products. Through the co-promotion of Riona, it will endeavour to further strengthen its presence in the market.
By co-promoting Riona with ASKA, which has extensive experience in the obstetrics and gynecology area, Torii believes that it will be able to provide wider information about Riona more effectively for relevant medical professionals.
Through these co-promotion activities, Torii and ASKA intend to build a close collaborative relationship, with the aim of the early establishment of Riona as a new option to help patients with iron deficiency anemia.
ABOUT Riona Tablets 250mg
'Riona Tablets 250mg' is approved and marketed for the treatment of hyperphosphatemia in adult patients with chronic kidney disease (CKD) both on dialysis and not on dialysis in
In
ABOUT IDA
IDA is the most frequent anemia, which is caused by decreasing hemoglobin production due to iron deficiency. IDA involves symptoms of anemia with palpitations and shortness of breath, as well as pica, fatigability, etc., which leads to the decrease in the patient's quality of life. The treatment for IDA is the iron supplementation and the correction of the underlying cause.
Contact:
Tel: +81-3-3231-6814
Email: webmaster@torii.co.jp
(C) 2020 Electronic News Publishing, source
